Biogen Inc(BIIB-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low231.04
Day High236.00
Open:231.81
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Zacks Investment Research
AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results
AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results
GlobeNewswire
Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week
Tipranks
Wells Fargo Sticks to Their Buy Rating for Biogen (BIIB)
Tipranks
Citi Remains a Hold on Biogen (BIIB)
StockStory
Biogen (BIIB) Stock Is Up, What You Need To Know
BIIB
StockStory
2 Surging Stocks for Long-Term Investors and 1 We Brush Off
BIIB
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Liquidia Technologies (LQDA), Kodiak Sciences (KOD)
Tipranks
Piper Sandler Keeps Their Buy Rating on Biogen (BIIB)
Tipranks
Biogen’s Salanersen Trial Strengthens Its SMA Pipeline Outlook
Tipranks
Analysts Offer Insights on Healthcare Companies: Orchestra BioMed Holdings (OBIO) and Biogen (BIIB)
GlobeNewswire
Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
Zacks Investment Research
Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise?
Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise?
Tipranks
Jefferies Keeps Their Buy Rating on Biogen (BIIB)
StockStory
1 Profitable Stock Worth Investigating and 2 We Ignore
MCRI
Tipranks
Analysts Conflicted on These Healthcare Names: Harmony Biosciences Holdings (HRMY), BioNTech SE (BNTX) and Biogen (BIIB)
SYNDTGAM
Why this $1-billion money manager bought Pembina, PrairieSky and sold Netflix
Illustration of Chris Kerlow for The Mover. June 23/24, 2023. Illustration by Joel Kimmel
StockStory
Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack
BIIB
Tipranks
Analysts Offer Insights on Healthcare Companies: Neuronetics (STIM), Xenon (XENE) and Biogen (BIIB)
GlobeNewswire
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN

Profile

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
Market data provided by Barchart. Exchange delay details and data provider terms here. Information may be delayed, is provided 'as is' and is solely for informational purposes, and not for trading, investment or advice.